

Eliminating Tobacco-Related Disparities for Persons with Mental Illnesses:

Development and Implementation of a Tobacco Cessation Toolkit

Jeanette Waxmonsky, PhD Chad Morris, PhD Mandy Graves, MPH Alexis Giese, MD



# **Objectives**

- Discuss the unique challenges and barriers
- Review evidence-based guidelines for tobacco cessation
- Describe the development and dissemination of a mental health provider toolkit
- Present preliminary data from a randomized study of tobacco cessation strategies



### Prevalence of Tobacco Use

- 20% of Americans have mental illnesses at any point in time
- Are nicotine dependent at rates 2-3 times higher than the general population
- Represent 44.3% of the U.S. tobacco market
- Represent 7.1% of the total U.S. population but consume 34.2% of all cigarettes smoked

(Lasser K et al: JAMA 284:2606-10, 2000)

- Persons with mental illnesses die young
  - 20% shorter life span due to tobacco-related diseases




# Tobacco Use by Psychiatric Diagnosis

Schizophrenia	65-85%
Bipolar disorder	55-70%
Major depression	50-60%
Anxiety disorders	45-60%

Lasser K et al: JAMA 284:2606-10, 2000; NASMHPD 2006





# **Biological Predisposition**

- Nicotine enhances
  - concentration
  - information processing
  - learning
- Enhances mood
- May reduce medication side effects



# **Barriers to Tobacco Interventions System, Clinician, and Patient Factors**

- Stigma, Competing demands
- Tobacco as socialization activity, behavioral reward
- Staff acceptance, promotion
- Fear of symptom exacerbation
- Lack of training
- Expectation of failure
- Lack of recovery
- Other substance abuse







University of Colorado SCHOOL OF MEDICINE Advancing Science Improving Care.





### **Cessation Rates**

Although quit rates for persons with mental illnesses are less than the general populations, smoking cessation rates are still substantial.

Major depression- up to 38% (Lasser et al., 2000)

Schizophrenia- between 10-30% (Addington et al., 1998; Baker et al., 2006)



### Treatment Recommendations

- Cognitive-Behavioral Therapy (CBT) + nicotine replacement therapy (NRT)
- Groups of approximately 8-10 individuals that meet once/week for 7-10 weeks
  - More person-to-person contact = better outcomes
- Individualized treatments based on diagnoses
- Stress consumer preference
- Address psychosocial needs that might undermine tobacco cessation
- Cessation may produce rapid, significant increase in medication blood levels
- Monitor for side effects, depression, weight gain



## **Pharmacotherapy**

# All smokers trying to quit should receive pharmacotherapy

(US Clinical Practice Guidelines)

- Nicotine replacement therapy (NRT)
- Bupropion SR
- Varenicline (Chantix—Pfizer)
- Clonidine\*
- Nortriptyline\*

\*Not FDA-approved for tobacco cessation




### The Colorado Model


- 2004 & 2006 Statewide Focus Groups
- Prevalence Studies
- Toolkit for Mental Health Providers
- Wellness Group Manual
- Randomized Study of Cessation Strategies
- Peer-to-Peer Interventions
- Primary Care
- Other Disparities Groups







Smoking Cessation for Persons with Mental Illnesses A Toolkt for Mental Health Providers










#### The Study Intervention (N = 123)



### Wellness Group Sessions

Session 1 Introduction to the program

Session 2 Working with the positives (strengths)

Session 3 How smoking affects your body

Session 4 Building self-confidence

Session 5 Dealing with stress and developing

supportive relationships

Session 6 Healthy ways of dealing with feeling down

Session 7 Dealing with strong negative feelings

Session 8 Healthy Lifestyle (Diet and exercise)

Session 9 Planning for high-risk situations

Session 10 Celebrating the road to recovery



# **Study Measures**

OUTCOME DOMAIN Patient Level	MEASURE
Tobacco Use	Fagerstrom Test for Nicotine Dependence (Heatherton, Kozlowski, Frecker, & Fagerstrom, 1991; Payne, Smith, McCracken, McSherry, & Antony, 1994) CO Monitor (objective measure of tobacco use)
Clinical Outcome	Brief Psychiatric Rating Scale (BPRS) (Overall & Gorham, 1962) Hamilton Depression Rating Scale (HAM-D) (Hamilton, 1960)
Functioning / Quality of Life	SF-12 (Ware, Kosinski, & Keller, 1996)
Pharmacotherapy	Chart review of evidence-based treatment
Self-Efficacy	Self-Efficacy items from Snyder Hope Scale (Snyder et al., 1996)
Motivational Stage- Readiness for Change	Motivational Stage of Change- Contemplation Ladder (Baker et al., 2002)



### **Preliminary 3-Month Outcomes**

- Significant decrease in self-reported average number of cigarettes smoked per day across all three groups, <u>F(3,83)=3.77, p>.0002.</u>
- All three groups had significantly lower rates of tobacco dependence from baseline as measured by the Fagerstrom test (p<.01), but did not differ across groups.</li>
- Scores on the HAM-D and BPRS showed a significant decrease in depressive and psychotic symptoms respectively over time for all groups (<u>p</u><.01) but did not differ across groups.

### **Next Steps**

- Collect 6- and 12- month follow up assessment data as well as QuitLine and medical chart data
- Determine quit rates
- Expand model to additional sites in Colorado
- Expand model to additional populations



### **Contact Information**

Jeanette Waxmonsky, Ph.D.

UCDHSC, Dept. of Psychiatry

Campus Box A011-11

4455 E. 12th Ave

Denver, CO 80220

(p) 303.315.9155

(f) 303.315.9343

jeanette.waxmonsky@uchsc.edu



"Even though this is hell, I still want it to be a healthy environment. So no, you can't smoke."

@ QuitSmoking.com

www.quitsmoking.com

